ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma (2021-2024)
Experts
Associate Professor
Colm Keane
Principal Research Fellow
Frazer Institute
Faculty of Health, Medicine and Behavioural Sciences
